Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOXO1 | Q12778 | 13/20 | 0.74 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.61 |
| ▸ | NPC1 | O15118 | 1/20 | 0.61 |
| ▸ | RAB9A | P51151 | 1/20 | 0.61 |
| ▸ | PDE10A | Q9Y233 | 3/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | ACHE | P22303 | 1/20 | 0.52 |
| ▸ | LDLR | P01130 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24513595 | 0.85 | FOXO1 (1.00) | FOXO1SMN1; SMN2NPC1RAB9APDE10A | |
| SCHEMBL22489142 | 0.77 | FOXO1 (0.80) | FOXO1SMN1; SMN2PDE10AACHE | |
| SCHEMBL24512908 | 0.76 | FOXO1 (0.80) | FOXO1NPC1RAB9APDE10AACHE | |
| SCHEMBL22489139 | 0.76 | FOXO1 (0.77) | FOXO1PDE10AACHE | |
| SCHEMBL22489135 | 0.76 | FOXO1 (0.77) | FOXO1SMN1; SMN2PDE10AACHE | |
| SCHEMBL25429204 | 0.75 | FOXO1 (0.64) | FOXO1PDE10AACHE | |
| SCHEMBL30754034 | 0.75 | FOXO1 (0.64) | FOXO1PDE10AACHE | |
| SCHEMBL13679710 | 0.75 | TP53 (0.67) | SMN1; SMN2NPC1RAB9AMAPTHTT | |
| SCHEMBL25427295 | 0.74 | FOXO1 (0.71) | FOXO1PDE10AACHE | |
| SCHEMBL29524272 | 0.74 | FOXO1 (0.71) | FOXO1PDE10AACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220185797-A1 | SELECTIVE FOXO INHIBITORS FOR TREATMENT OF DIABETES AND OTHER DISORDERS RELATED TO IMPAIRED PANCREATIC FUNCTION | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2022-06-16 | — | — | US | disclosed |
| WO-2020198351-A1 | SELECTIVE FOXO INHIBITORS FOR TREATMENT OF DIABETES AND OTHER DISORDERS RELATED TO IMPAIRED PANCREATIC FUNCTION | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2020-10-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220185797-A1 | SELECTIVE FOXO INHIBITORS FOR TREATMENT OF DIABETES AND OTHER DISORDERS RELATED TO IMPAIRED PANCREATIC FUNCTION | FOXO1, FOXO3, FOXK1 | FOXO1 1/4885SMN1; SMN2 478/4885NPC1 3743/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.